Karl-Erik Andersson to Receptor, erbB-2
This is a "connection" page, showing publications Karl-Erik Andersson has written about Receptor, erbB-2.
Connection Strength
0.760
-
Gedda L, Björkelund H, Lebel L, Asplund A, Dubois L, Wester K, Penagos N, Malmqvist M, Andersson K. Evaluation of real-time immunohistochemistry and interaction map as an alternative objective assessment of HER2 expression in human breast cancer tissue. Appl Immunohistochem Mol Morphol. 2013 Dec; 21(6):497-505.
Score: 0.397
-
Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm. 2013 Apr; 28(3):187-95.
Score: 0.094
-
Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem. 2012 Sep 19; 23(9):1802-11.
Score: 0.091
-
Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007 Mar 15; 67(6):2773-82.
Score: 0.062
-
Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006 May; 47(5):846-53.
Score: 0.059
-
Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1457-62.
Score: 0.056